(Total Views: 683)
Posted On: 01/01/2024 7:58:02 PM
Post# of 154604
Patient population is about 145,000 annually...targets low PD-L1...
The company is CEL-SCI... the Cancer product Multikine is used for 3 weeks prior to surgery...apparently reduces size etc. and then SOC....trades at ten times our current value...they have had talks with Merck.
Ohm...your thoughts...not as an investment...but as a Cancer treatment.
The company is CEL-SCI... the Cancer product Multikine is used for 3 weeks prior to surgery...apparently reduces size etc. and then SOC....trades at ten times our current value...they have had talks with Merck.
Ohm...your thoughts...not as an investment...but as a Cancer treatment.
(2)
(0)
